Tonix Pharmaceuticals Holding (TNXP) Current Deferred Revenue (2012 - 2026)

Tonix Pharmaceuticals Holding has reported Current Deferred Revenue for 6 years, with the latest figure at $3.8 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 26.9% year-over-year to $3.8 million in Q2 2026; TTM through Jun 2026 was $3.8 million, a 26.9% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 88.6% from the prior year.
• Current Deferred Revenue was $3.8 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from $4.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $4.2 million in Q1 2026, with the low at $1.8 million in Q4 2024.
• Average Current Deferred Revenue over 5 years is $3.0 million, with a median of $3.0 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue sank 39.06% in 2024, then soared 118.56% in 2026.
• Over 5 years, Current Deferred Revenue stood at $3.3 million in 2022, then decreased by 8.95% to $3.0 million in 2023, then tumbled by 39.06% to $1.8 million in 2024, then jumped by 88.6% to $3.4 million in 2025, then advanced by 11.42% to $3.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $3.8 million (Q2 2026), $4.2 million (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.